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EditorialTaking a Healthy Interest in Translational ResearchIt is now readily possible to determine, often in exquisite detail,
the ways in which a single cell or a single individual differs from
another. Although we are rapidly figuring out how these cellular
features are altered in disease states, pulling medical advances
from this haystack of facts remains a challenge. Yet, the view
from Cell on prospects for medical advancement in this era of
integrated ‘‘omics’’ could be summed up in a single word: opti-
mistic. From our daily engagement with researchers in pursuit
of the most exciting scientific discoveries, we feel a palpable
acceleration of interest and enthusiasm in translational work
occurring within the community.
Cell has a key role in fostering this essential dialog between
the research and medical fields, and we’re eager to continue
pushing the boundaries of how we think about disease and its
treatment. Papers that resonate with both communities come
in many varieties, and you can find examples in our recent issues
that include enhancing transplantation efficiency for stem cells
derived from cord blood (http://www.cell.com/cell/abstract/
S0092-8674(15)00574-7), using organoids for personalized drug
screening (http://www.cell.com/cell/abstract/S0092-8674(15)
00373-6), suggesting new combination treatments in cancer
immunotherapy (http://www.cell.com/cell/abstract/S0092-8674
(15)01040-5 and http://www.cell.com/cell/abstract/S0092-8674
(15)01028-4), and exploring antibody-based treatments for
cachexia (http://www.cell.com/cell/abstract/S0092-8674(15)
01045-4). Also as part of our commitment to the dialog across
the medical-research divide, Cell Press has recently joined
forces with The Lancet group of journals to support the launch
of an exciting new open access journal, EBioMedicine, with
the aim of creating a forum to bring a community of scientists
and physicians together toward the shared goal of improving
human health.
As we expand into more translational and clinical arenas, we
need to educate ourselves about publication standards and con-
cerns in more clinical fields while building our pool of qualified
rigorous reviewers. For example, we find that many disease-ori-
ented studies increasingly include testing of compounds or com-
bination therapies in mouse models, and a major bottleneck for
these efforts is to improve reproducibility and the success rate
of new prospective treatments through the pre-clinical and clin-
ical development pipeline. Glenn Merlino and colleagues on
page 39 of this issue tackle this matter of improving the ability
of pre-clinical models in cancer to predict successful
outcomes in human trials and highlight new approaches. We
are also observing an increasing number of studies crossing
our transom that take advantage of patient samples and other
human data to support a proposed target’s therapeutic poten-
tial. For these, we need to pay special attention to issues of con-
sent and patient confidentiality and to the importance of study
design and the use of appropriate statistics in assessing clinical
data. Overall, the engagement of our community of researchers
with the therapeutic development pipeline is robust and
strengthening. With the accelerating pace at which new discov-
eries are informing new potential treatments, it is now possible toenvision a time in the not too distant future when a paper in Cell
could include both basic insights and results from randomized
human clinical trials.
In the world of translational research, a landmark event is
governmental approval of a new drug or therapeutic, which
directly impacts how a disease is treated and offers new hope
for patients. To celebrate these achievements and help promote
the conversation between basic scientists, pharma/biotech, and
physicians, we’ve recently launched a new format called ‘‘Bench
to Bedside.’’ On page 17, you will see our latest feature, which
looks at Orkambi, a combination therapy that promotes the cor-
rect folding of the mutated channel that causes cystic fibrosis.
Following its approval, it is expected that up to 50% of patients
will benefit, marking a major milestone for a difficult-to-treat dis-
ease and highlighting protein folding as a medically targetable
aspect of cell biology. All of this stems from the discovery
more than 20 years ago that the disease is caused by mutations
in a channel protein that impair its trafficking to the cell surface
and promote its degradation (http://www.cell.com/cell/
abstract/0092-8674(90)90148-8).
For the bench researcher, Bench to Bedside will keep you
abreast of exciting developments in new drugs and biologics.
For the clinician, we aim to provide a succinct reference that con-
veys how the treatment works and the biological discoveries that
made it possible. The timelines of key discoveries that feature in
each Bench to Bedside hammer home the societal impact of
sustained investment in research, and we hope that these will
spark pride in what the research, pharma, and medical commu-
nities have together accomplished.
As a community, it is essential that wemake clear to the public
and to policymakers the ways in which basic and translational
discoveries contribute to new treatments. On page 21 of this
issue, Sanders Williams and colleagues present a Commentary
that advocates for greater use of data mining and network anal-
ysis in assessing the individual and institutional contributions to
recently approved treatments. They create a new bioinformatics
tool, and using the example of ivacaftor (a component of
Orkambi), they establish that the timeline of key discoveries in
the cystic fibrosis field goes backnearly six decades and includes
efforts frommore than 2,000 researchers. The analyses also pro-
vide insight into the most influential researchers and institutions
for a given breakthrough, offering quantifiable validation for why
long-term thinking matters when it comes to research funding.
When Cell was founded four decades ago, the molecular
biology revolution was exploding, powered by recombinant
DNA technologies. This is when Cell established the roots that
still nourish its pages today. Staying at the cutting edge ever
since has led us in new areas, and today one of these areas
that is rapidly expanding, powered by new omics technologies
and mechanism-based drug development, is translational
research. Being explicit in our advocacy and interest in transla-
tional work comes at the risk of some fearing that Cell ‘‘won’t
like my paper because it doesn’t have a translational message.’’
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interest in translational potential as one of the many elements
considered when evaluating a study, and so this editorial
perspective is not new. More to the point, conceptual impact—
from whatever source or discipline—is our guiding principle,
and we will continue to aggressively pursue and publish what
is most exciting in basic biological research. Even as we remain6 Cell 163, September 24, 2015 ª2015 Elsevier Inc.firmly grounded by our roots, we see in the current era a lifting of
the fog between basic biological insight and clinical treatment
that is making the shorelines of each visible to the other. This
process will shape how these disciplines cross-pollinate, and
as journal, we are dedicated to amplifying and enhancing the
speed of this exchange.The Cell editorial team
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